others to step forward and invest in solutions that truly make a difference."Delivering Medically Tailored MealsA partnership with Project Angel Food delivered over 1 million medically tailored meals annually to Medi-Cal members through CalAIM from 2023 to 2025. In addition to meal delivery, the program provides twice-daily medically tailored meals for at least 12 weeks and includes nutrition counseling designed to improve health outcomes, support chronic disease management, and enhance overall well-being f ...

Key Takeaways UnitedHealthcare revenues rose 15.7% to $344.9B in 2025, but operating earnings fell 41.1%.Medical care ratio climbed to 89.1% as margins shrank; 2026 earnings seen above $10.8B.UnitedHealth 2026 revenue expected above $439B, below 2025's $447.6B, amid MA rate concerns.UnitedHealth Group Incorporated’s (UNH) health benefits arm, UnitedHealthcare, remains the company’s primary revenue engine, yet profitability pressures continue to weigh on investor sentiment. Although the segment’s revenues cl ...

AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2025 Results and Provides 2026 Financial Guidance-# AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2025 Results and Provides 2026 Financial GuidanceShare---CONSHOHOCKEN, Pa.--([BUSINESS WIRE])--AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth†or the "Company†), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial resul ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought agilon securities between February 26, 2025, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Agilon - The lawsuit alleges that during the Class Period, defendants made false and misleading statements and failed to disclose critical information, including: 1. Reckless issuance of guidance for 2025 that was unlikely to be achieved due to known industry challenges 2. Material overstatement of the financial impact from strategic actions taken by agilon to mitigate risk 3. Overall misleading statements regarding agilon's business, operations, and prospects [5].

Market Overview - The S&P 500 is down by 0.1% but remains near record highs, with defensive sectors gaining traction [2] - The ten-year Treasury yield has decreased by almost six basis points to 4.14%, influenced by weak retail sales data, which strengthens the case for potential Fed rate cuts [3][5] - Bitcoin has experienced volatility, currently trading just below $69,000 after reaching $60,000 last week [4] Economic Indicators - December retail sales showed stagnation, with eight out of thirteen retail categories reporting declines, indicating potential weakness in consumer spending [5][20] - The upcoming January jobs report is anticipated to provide further insights into the labor market, with a consensus estimate of 65,000 new jobs, although a whisper number suggests only 40,000 [26][28] Company Insights - Goldman Sachs CEO David Solomon expressed confidence in the U.S. economy, suggesting that the recent drop in software stocks may have been overdone [6][7] - Quest Diagnostics reported a record high in shares following strong earnings, raising its dividend and issuing a higher-than-expected adjusted EPS forecast for 2026 [30][31] - The consumer health segment of Quest Diagnostics is projected to grow over 20% this year, driven by increased consumer interest in preventive health measures [36][37] Sector Performance - Small-cap stocks, represented by the Russell 2000, have outperformed large-cap stocks, with a 21% rally over the past six months compared to a 9% gain for the S&P 500 [9][10] - The software sector has seen a significant valuation rerating of about 40% recently, despite facing scrutiny and volatility [15][19] - The healthcare sector, particularly in diagnostics and chronic disease management, is experiencing growth due to rising rates of chronic conditions and advancements in testing technologies [32][44] Future Outlook - The U.S. economy is transitioning from labor force growth to productivity-led growth, with generative AI adoption contributing to a productivity growth rate of 2% over the past few years, surpassing pre-COVID levels [25][98] - CVS is facing challenges due to flat Medicare Advantage rates, which could impact its growth trajectory, particularly as it targets mid-teens EPS growth through 2028 [52][54] - Becton Dickinson's recent merger with Waters aims to position the company as a leader in the life sciences space, focusing on AI and robotics to enhance healthcare delivery [67][68]

Group 1 - CVS Health Corporation (NYSE:CVS) is increasingly viewed as a managed care company rather than a traditional drug store, primarily due to its acquisition of Aetna [1] - The stock has faced significant pressure recently, particularly after the government announced minimal increases in reimbursement rates for Medicare Advantage plans, which negatively impacted health insurers [1] - CVS Health provides a range of healthcare solutions, including insurance, pharmacy benefit management, and retail pharmacy services [3] Group 2 - While CVS is recognized for its potential as an investment, there are AI stocks that are perceived to offer greater upside potential and lower downside risk [4]

Core Insights - Sequoia Strategy achieved a return of 9% in Q4 2025, outperforming the S&P 500 Index which returned 2.7% during the same period [1] - For the entire year of 2025, Sequoia Strategy delivered a return of 21.9%, compared to 17.9% for the S&P 500 Index [1] - The Strategy focuses on investing in high-quality, fundamentally and financially strong businesses at reasonable prices, covering a wide range of sectors, business styles, and regions [1] Company Performance - Elevance Health, Inc. (NYSE:ELV) detracted from the Strategy's performance in Q4 2025, with a one-month return of -11.65% and a 12-month decline of 16.29% [2] - As of February 9, 2026, Elevance Health, Inc. had a market capitalization of $72.281 billion [2] - The investments in Elevance Health and UnitedHealth Group Inc. were initiated opportunistically, with Elevance shares purchased two years after a significant impact from COVID-19 on healthcare utilization [3]

Core Insights - Sequoia Strategy achieved a return of 9% in Q4 2025, outperforming the S&P 500 Index which returned 2.7% during the same period [1] - For the entire year of 2025, Sequoia Strategy delivered a return of 21.9%, compared to 17.9% for the S&P 500 Index [1] - The Strategy focuses on investing in high-quality, fundamentally and financially strong businesses at reasonable prices, covering a wide range of sectors, business styles, and regions [1] Company Performance - UnitedHealth Group Incorporated (NYSE:UNH) negatively impacted the Strategy's performance in Q4 2025, with a one-month return of -17.44% and a 12-month decline of 48.36% [2] - As of February 9, 2026, UnitedHealth Group's stock closed at $275.70 per share, and the company has a market capitalization of $249.74 billion [2] - The investments in UnitedHealth Group and Elevance Health were initiated opportunistically, with UnitedHealth shares purchased during a price drop in 2019 due to "Medicare for All" concerns [3]

Core Viewpoint - Centene expects a rebound in 2026 with adjusted EPS greater than $3, implying over 40% year-over-year growth, driven by Medicaid margin stability, significant margin recovery in Marketplace, and continued improvement toward Medicare Advantage break-even by 2027 [1][4][7] Medicaid - Centene reported a fourth-quarter health benefits ratio (HBR) of 93.0%, showing a 40 basis points sequential improvement and 190 basis points improvement from Q2 levels [8] - The company anticipates a mid-4% net rate impact and mid-4% net trend for 2026, while expecting ongoing Medicaid membership attrition, closing 2025 at 12.5 million members [11][12] - Management is focused on restoring sustainable profitability in Medicaid through operational levers such as network optimization and clinical programs [9] Marketplace - The Marketplace segment is expected to face a smaller membership base due to the expiration of Enhanced Advance Premium Tax Credits (EAPTC), with Ambetter membership projected at approximately 3.5 million by Q1 2026, down from 5.5 million in December [5][15] - Centene anticipates Marketplace pre-tax margins to recover to around 4% in 2026, compared to a loss of approximately 1% in 2025 [17] - The company has accounted for estimated 2026 No Surprises Act costs in its guidance and is advocating for reform [14] Medicare - Centene's Medicare segment is expected to grow premium revenue by about $7.5 billion, with membership projected at approximately 8.7 million coming out of open enrollment [20] - The company aims for break-even results in Medicare Advantage by 2027, with dual-eligible members making up roughly 40% of its Medicare Advantage business [19] - The direct subsidy for Part D increased from $143 to $200, which is expected to raise the HBR without requiring higher SG&A [21] Financial Guidance - For 2026, Centene guided premium and service revenue between $170 billion and $174 billion, with a consolidated HBR of 90.9% to 91.7% [23][24] - The company expects the majority of 2026 adjusted EPS to occur in Q1, with a step-down through the year and a loss anticipated in Q4 [26] - Centene ended 2025 with approximately $400 million in cash for corporate use and reduced debt by $189 million in Q4, reporting a debt-to-cap ratio of 46.5% [25]

Core Viewpoint - Molina Healthcare's shares plummeted over 25% following disappointing guidance for fiscal 2026, with earnings projected at $5 per share, significantly lower than the previous estimate of approximately $14 [1]. Group 1: Stock Performance - Year-to-date, Molina Healthcare's stock has declined nearly 35% from its high [2]. - The stock is currently trading below its major moving averages, indicating a broader downward trend [7]. Group 2: Financial Guidance and Market Reaction - The company anticipates an elevated medical cost ratio for the year, contributing to the lowered earnings guidance [1]. - Despite the sharp decline, investor Michael Burry remains optimistic about his investment in Molina, comparing it to Berkshire Hathaway's investment in Geico [4]. Group 3: Investment Considerations - Molina Healthcare is currently trading at a discount to its intrinsic value, but faces increased pressure from proposed reductions in Medicare Advantage reimbursement rates, making it a high-risk investment [5]. - Unlike competitors such as UnitedHealth and Humana, Molina does not pay a dividend, making it less attractive for income-focused investors [5]. - Options traders express skepticism about the stock's recovery, with predictions indicating a potential further decline of 20% over the next five months [7]. Group 4: Analyst Perspectives - Wall Street analysts suggest that the recent selloff in Molina shares may have been excessive, indicating potential for recovery despite the associated risks [9].